Kadimastem In the News

August 05, 2020

See what ALS News Today has to say about our AstroRx® Product

The ALS News Today published a very positive article written by Inês Martins, PhD who states: "A pooled analysis of all 10 patients included in the trial showed that AstroRx® reduced the disease progression rate by 53%" Read this informative article on our latest published findings from Interim of Cohort B in our phase 1/2a clinical trial on ALS patients. Click here to read the article. 

November 21, 2019

Catch us presenting at the Stem Cell Community Day 2019: Bringing the global stem cell research community together on November 21 in Portugal

Kadimastem was pleased to be part of the amazing stem cell Community leading the path to innovative promising treatments. Using DASBox, Eppendorff. Click here for event details. 

October 03, 2019

The Times of Israel writes about our clinical trial for ALS

The times of Israel article by Shoshanna Solomon writes that Israeli company Kadimastem says interim results of first patient group indicate new drug ‘managed to significantly slow down disease progression’. Click here for the full article. 

January 05, 2020

Kadimastem kicks off 2020 with good news

The Jerusalem Post article by Maayan Jaffe-Hoffman illustrates our current clinical trial with AtroRx® for the treatment of ALS and its abilities to replace functioning of damages cells using Allogenic "off the shelf" stem cells. Click here for the full article

November 14, 2019

NoCamels writes about Kadimastem's cutting edge technology that stands out!

NoCamels article by Simona Shemer writes about Israeli companies that are driving innovation in diabetes care and treatment, she writes about Kadimastem and our "off the shelf" product IsletRx in pre-clinical trials for the treatment of Type 1 Diabetes. Click here for the full article. 

November 24, 2019

Kadimastem to speak at II International Symposium about ALS

Northeast walking hand in hand Conference in Maceió, Brazil. We will present AstroRx® cell therapy technology for the treatment of ALS patients; from bench to patient bedside!

January 14, 2017

Dont miss Arik Hasson, PhD, Exec. VP, of R&D present at the 7th international Stem Cell Meeting

Arik is Present Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS at the 7th International Stem Cell Meeting, in Tel-Aviv, Israel. Previously announced interim results demonstrated reduced disease progression in the first 3 months post-treatment period with AstroRx®. Click here for a link to the Meeting Site.

© 2020 by Kadimastem

  • White Facebook Icon
  • White Twitter Icon
  • White LinkedIn Icon